Loomis Sayles & Co. L P Sells 19,679 Shares of Glaukos Co. (NYSE:GKOS)

Loomis Sayles & Co. L P lowered its holdings in shares of Glaukos Co. (NYSE:GKOS) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 654,072 shares of the medical instruments supplier’s stock after selling 19,679 shares during the quarter. Loomis Sayles & Co. L P owned 1.19% of Glaukos worth $98,072,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the business. Wellington Management Group LLP boosted its position in Glaukos by 294.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,183,766 shares of the medical instruments supplier’s stock valued at $284,501,000 after buying an additional 1,630,270 shares during the period. William Blair Investment Management LLC purchased a new stake in shares of Glaukos in the fourth quarter valued at approximately $121,390,000. Charles Schwab Investment Management Inc. grew its stake in Glaukos by 47.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 641,761 shares of the medical instruments supplier’s stock worth $83,609,000 after purchasing an additional 207,338 shares in the last quarter. Raymond James Financial Inc. bought a new position in Glaukos in the fourth quarter worth approximately $16,910,000. Finally, Vanguard Group Inc. raised its position in Glaukos by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 5,974,971 shares of the medical instruments supplier’s stock valued at $895,887,000 after purchasing an additional 101,838 shares in the last quarter. Institutional investors own 99.04% of the company’s stock.

Glaukos Stock Performance

Shares of GKOS stock opened at $103.26 on Thursday. The stock has a market cap of $5.84 billion, a PE ratio of -35.98 and a beta of 0.99. Glaukos Co. has a 52-week low of $88.16 and a 52-week high of $163.71. The business has a 50-day simple moving average of $132.68 and a 200-day simple moving average of $136.06. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). The company had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. On average, equities analysts expect that Glaukos Co. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on GKOS. Wells Fargo & Company raised their price target on Glaukos from $153.00 to $160.00 and gave the company an “overweight” rating in a research note on Friday, February 21st. Needham & Company LLC upped their price target on shares of Glaukos from $149.00 to $176.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Stifel Nicolaus increased their price objective on shares of Glaukos from $153.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, December 31st. Stephens raised shares of Glaukos to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $180.00 target price (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Insiders Place Their Bets

In related news, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the transaction, the insider now directly owns 72,437 shares of the company’s stock, valued at $10,658,380.18. The trade was a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.40% of the stock is owned by insiders.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.